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Clostridium difficile causes antibiotic- and healthcare-associated diarrhea, which is
characterized by a high mortality rate (5–15%) and high recurrence rate of 20% or
more. Therapeutic alternatives to antibiotics are urgently needed to improve the overall
cure rate. Among these, therapeutic antibodies have shown promising results in clinical
studies. Herein, the authors review current monoclonal and polyclonal anti- C. difficile
antibodies that have entered the clinical development stage, either for systemic
administration or by the oral route. The antibodies can be applied as monotherapy or
in combination with standard-of-care to treat an infection with C. difficile or to protect
from a recurrence. Bezlotoxumab is the first antibody for secondary prevention of
recurrence of C. difficile infection approved by the regulatory agencies in US and Europe.
The human monoclonal antibody is administered systemically to patients receiving oral
standard-of–care antibiotics. Other antibodies are currently in the clinical pipeline, and
some are intended for oral use. They show a good safety profile, high efficacy and low
production costs, and can be considered promising therapies of the future. The most
promising orally administered drug candidate is a bovine antibody from hyperimmune
colostral milk, which is in an advanced clinical development stage. Which antibody will
enter the market is dependent on its bioavailability at the site of infection as well as its
activity against C. difficile toxins, protection against colonization and possible action on
spore formation. The antibody must demonstrate a clear benefit in comparison with other
available treatment options to be considered for use by clinicians.
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INTRODUCTION
Clostridium difficile (CD) is an anaerobic spore-forming bacterium that can be present in the gut of
asymptomatic CD carriers (Crobach et al., 2018). However, it is also the most important cause of
infectious antibiotic- and healthcare-associated diarrhea (Rupnik et al., 2009; Magill et al., 2014). In
patients developing symptomatic C. difficile infection (CDI), symptoms range from mild diarrhea
to fulminant life-threatening colitis (Smits et al., 2016).
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The conventional treatment of CDI consists of vancomycin
or metronidazole, which are non-selective and lead to further
disruption of normal gut microbiota, consequently placing
patients at risk for relapse or recurrence. Approximately 25%
of CDI patients experience recurrent disease, which is often
difficult to treat (Cornely et al., 2012). Alternatively, fidaxomicin
is considered to be a specific anti-C. difficile antibiotic, but its
application is restricted due to high costs. Recently, antibody-
mediated therapies for treatment or prevention of CDI have
gained attention as alternatives to antibiotic treatment. Here,
we discuss the rationale behind antibody-mediated therapy and
describe the diverse antibody-mediated therapies (excluding
active immunization by vaccines) that are currently studied in
the clinic for treatment or prevention (of recurrences) of CDI in
humans.
ROLE OF HUMORAL ACTIVITY AGAINST
C. DIFFICILE
Several studies have demonstrated that the adaptive immune
response plays an important role in CDI susceptibility, disease
course and risk of recurrence. CDI symptoms are caused by
the actions of two large enterotoxins, toxin A (TcdA) and B
(TcdB). After the secreted toxins have bound and entered the
colonic epithelium, TcdA and TcdB can induce an inflammatory
response characterized by chemokine and cytokine production,
neutrophil influx, disruption of tight junctions, fluid secretion
and cell death (Péchiné and Collignon, 2016; Smits et al., 2016).
Some strains, including the more virulent ribotypes 027 and 078,
also produce a third toxin, termed binary toxin or CD transferase
(CDT). CDT is suggested to causemicrotubule-based protrusions
on epithelial cells, thereby increasing the adherence of CD to
target cells (Smits et al., 2016; Aktories et al., 2018). However,
its definite role in pathogenesis remains unclear. CD surface
proteins, which mainly act as adhesins, include S-layer proteins,
flagellar proteins FliC and FliD and cell wall proteins (Cwps)
such as Cwp84. These surface proteins also contribute to the
initiation of the inflammatory response via cytokine production
and interaction with toll-like receptors (Péchiné and Collignon,
2016). Inflammation induced by the innate immune response
promotes an adaptive immune response with memory.
Both antibodies to CD toxins and surface proteins have
been described, and the adequacy of the humoral immune
response can influence susceptibility to CD colonization and/or
progression to CDI. In 55 CDI patients, significantly higher
serum IgM anti-SLP (S-layer proteins) antibody levels were
found at the initial episode in non-CDI recurring patients
compared to patients who went on to develop recurrent CDI
(rCDI) (Drudy et al., 2004). Furthermore, serum antibody levels
for surface proteins, including FliD and FliC, were significantly
higher in control patients than in CDI patients (Péchiné et al.,
2005). Therefore, antibodies against CD surface proteins are
thought to have a protective role against (re)colonization.
Anti-TcdA and anti-TcdB antibodies can protect colonized
patients from progression to CDI or recurrent disease. Anti-toxin
antibodies are present in the general population, and antitoxin
seropositivity prevalence in the general population of 24 or 66%
have been previously reported (Viscidi et al., 1983; Bacon and
Fekety, 1994). Anti-TcdA antibody levels have also been studied
in hospitalized patients receiving antibiotic treatment. After
intestinal colonization with C. difficile, greater increases in serum
levels of anti-TcdA IgG were reported in those patients who
remained asymptomatic, compared to those who progressed to
CDI. Serum anti-TcdA IgG increased rapidly after colonization,
indicating the presence of a systemic anamnestic response to
TcdA after day three (Kyne et al., 2000). Furthermore, the
development of higher serum anti-TcdB and anti-TcdA IgG levels
and fecal anti-TcdA IgA levels during the course of CDI were all
reported to be associated with a lower risk of rCDI (Aronsson
et al., 1985; Warny et al., 1994). In another study, higher anti-
TcdA IgM and IgG levels at day 12 were associated with a lower
risk of recurrence (Kyne et al., 2001). Anti-toxin antibodies may
be directly protective against disease by neutralizing secreted
toxin. The association of anti-toxin antibodies with decreased
recurrence risk may be explained by their ability to remove the






In 2017, bezlotoxumab (Zinplava©) was approved by the Food
and Drug Administration (FDA), and 1 year later by the
European Medicines Agency (EMA), as the first monoclonal
antibody for prevention of rCDI in patients ≥18 years old.
Actoxumab and bezlotoxumab were developed in parallel
as fully human monoclonal IgG (HuMAbs) directed against
TcdA and TcdB respectively. Inactivated TcdA and TcdB
(both from Techlab), and additionally recombinant TcdB,
were used as antigens to immunize mice transgenic for
human immunoglobulin genes (HuMAb mice, Medarex Inc.,
Bloomsbury, New Jersey) (Babcock et al., 2006). Various
hybridomas were obtained and screened in vitro and in vivo. The
lead candidate against TcdA (CDA1) recognized the C-terminal
region of TcdA and could prevent binding to a cognate receptor
on the surface of target cells. The lead candidate against TcdB
(MDX-1388) was proposed to bind to the N-terminal domain
(putative cell-binding region) of TcdB (Table 1).
A combination treatment with CDA1 and MDX-1388 in a
hamster model for primary disease and relapse showed the
best outcome. After safety and pharmacokinetics of CDA1
were assessed in healthy volunteers in a phase I clinical trial
(Taylor et al., 2008), efficacy of combination treatment with
CDA1 and MDX-1388 was examined in a randomized double-
blind, placebo-controlled phase II clinical trial (Lowy et al.,
2010). The addition of both antibodies to either metronidazole-
or vancomycin-treated patients with CDI significantly reduced
recurrence rates. The recurrence rate of patients in the treatment
group was 7%, compared to 25% in the placebo group (Table 2).
No significant differences were found in disease severity, number
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TABLE 1 | Clinically tested antibody-mediated therapeutic agents for CDI.
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IVIG, intravenous immunoglobulin; TcdA, C. difficile toxin A; TcdB, C. difficile toxin B; CDI, C. difficile disease; rCDI, recurrent CDI.
of days to resolution, or proportion of treatment failure. Adverse
events were reported to be similar in both groups.
The worldwide development and commercialization rights for
both antibodies were purchased by Merck for US$ 60 million,
(Markham, 2016) and two double-blind, placebo-controlled
phase III trials, MODIFY I and II, were conducted to assess
efficacy and safety of both antibodies (subsequently named
actoxumab and bezlotoxumab) (Wilcox et al., 2017). MODIFY
I had an adaptive design, allowing enrolment cessation in any
group after interim analysis. Patients were randomly assigned in
a 1:1:1:1 ratio to either receive a single dose of bezlotoxumab,
actoxumab, bezlotoxumab plus actoxumab or placebo in addition
to standard antibiotic treatment for CDI. During the interim
analysis of MODIFY I, higher mortality andmore serious adverse
events were found in the actoxumab group, causing enrolment
in this group to be terminated. Subsequently, actoxumab was
not evaluated in MODIFY II. While in both trials initial cure
rates did not differ between antibody-treated groups and placebo
groups, significantly lower recurrence of CDI was found in
the bezlotoxumab groups during 12 weeks post-treatment, as
recurrent infections were seen in 17 and 16% in these groups
in MODIFY I and II respectively, in comparison to 28 and 26%
in the placebo groups (Table 2). Subgroup analysis of initially
cured participants similarly showed significant differences in the
recurrence rate, while sensitivity analysis taking into account
missing data and early discontinuations were consistent with
these findings. The addition of actoxumab to bezlotoxumab did
not improve efficacy in MODIFY I. The overall safety profile of
bezlotoxumab was favorable, though the assessment reports of
FDA and EMA noted a numerical increment of heart failure and
all-cause mortality among bezlotoxumab treated subjects with
baseline congestive heart failure, compared to placebo-treated
patients.
The benefit of bezlotoxumab and actoxumab-bezlotoxumab
was confirmed in subpopulations at high risk for rCDI or
CDI complications. Post-hoc analyses of the two phase 3
trials (MODIFY 1 and MODIFY II) showed greater benefit
of bezlotoxumab than placebo in patients with at least three
risk factors. No difference in CDI recurrence was observed for
patients with no predefined risk factors (Gerding et al., 2018).
Bezlotoxumab is available for the retail price of $4,560 per
vial (Lee et al., 2017). In a model-based analysis of the MODIFY
trial subjects by the manufacturer, bezlotoxumab was reported
to be cost-effective compared to placebo (Prabhu et al., 2018),
although no reports of comparison to other approaches such as
fecal transplant or fidaxomicin treatment have been published.
Intravenous Immunoglobulin
In contrast to monoclonal antibody therapies, a cocktail of
synergistic polyclonal antibodies has the ability to bind multiple
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TABLE 2 | Studies evaluating antibody-mediated therapeutics in humans.
Agent Study (author, year) Study design Efficacy
SYSTEMIC APPLICATION ROUTE
Actoxumab (CDA1) Wilcox et al., 2017 Clinical Phase III study
MODIFY I:
Addition of actoxumab, bezlotoxumab, a-b or
placebo to SoC treatment in adult (r)CDI patients
Higher mortality and more AE in actoxumab
group; evaluation terminated
Bezlotoxumab (MDX1388) Wilcox et al., 2017 Clinical Phase III study
Addition of bezlotoxumab (n = 781) vs. placebo
(n = 773) to SoC treatment in adult (r)CDI
patients
MODIFY I No difference initial cure rate (77% vs. 83%)
Significant lower rCDI (17% vs. 28%)
MODIFY II No difference initial cure rate (83% vs. 78%)
Significant lower rCDI (16% vs. 26%)
Actoxumab-
bezlotoxumab
Lowy et al., 2010 Clinical Phase II study
Addition of CDA1+ and MDX1388 in single
infusion (n = 101) vs. placebo (n = 99) to SoC
treatment for CDI
Significant lower laboratory-documented rCDI:
7% comparator vs. 25% placebo
Wilcox et al., 2017 Clinical phase III study
Addition of actoxumab-bezlotoxumab (n = 773)
vs. placebo (n = 773) to SoC treatment in adult
(r)CDI patients
MODIFY I No difference initial cure rate (75% vs. 83%)
Significant lower rCDI(16% vs. 28%)
MODIFY II No difference initial cure rate (72% vs. 78%)
Significant lower rCDI (15% vs. 26%)
IVIG Leung et al., 1991 Case series
5 pediatric patients with hypoglobulinaemia and
rCDI, 400 mg/kg IVIG
All patients had full resolution of symptoms
Wilcox, 2004; McPherson
et al., 2006; Negm et al.,
2017
Retrospective studies
36 adult patients with (r)CDI, 150–500 mg/kg
IVIG
24 patients showed therapeutic response, 12
did not respond
Juang et al., 2007;
Shahani and Koirala, 2015
Retrospective studies
39 adult patients with severe CDI, 82 control
patients, 400 mg/kg IVIG
No significant differences regarding outcome
and severity of symptoms
ORAL APPLICATION ROUTE
IgAbulin Tjellström et al., 1993 Case study
1 pediatric patient with severe CDI
Full resolution of symptoms
MucoMilk van Dissel et al., 2005 Prospective cohort study
15 adult patients, 1 pediatric patient with
completed antibiotic therapy, under which 9
patients with rCDI
No relapse within a median follow-up period of
333 days
Numan et al., 2007 Prospective cohort study
101 adult patients, with completed antibiotic
therapy, 61 patients with CDI 40 patients with
rCDI (40%)
Prevention of relapse by 50% during a follow
up period of 60 days
Cediff Mattila et al., 2008 Prospective study
38 adult patients with rCDI
20 were treated with Cediff, 18 were treated with
metronidazole
Cediff was as effective as metronidazole in the
prevention of CDI recurrences during a 70 day
follow up (sustained recovery 56% vs. 55%)
a-b, actoxumab-bezlotoxumab; AE, adverse event; SOC, standard-of-care; CDI, C. difficile disease; CDA1, human monoclonal anti-toxin A; CDB1, human monoclonal anti-toxin B;
rCDI, recurrent CDI; SoC, standard-of-care antibiotic treatment for CDI; TcdA, C. difficile toxin A; TcdB, C. difficile toxin B; vs., versus; IVIG, intravenous immunoglobulin.
targets and mediate a variety of effector functions (Wang et al.,
2013).
Intravenous immunoglobulin (IVIG) is in use for numerous
clinically approved pathological conditions (Hässig, 1967; Stiehm
et al., 2008), and in more than 100 different indications as an
off-label drug (João et al., 2018). The rationale to apply IVIG to
patients with CDI is based on the prevalence of serum antibodies
against TcdA and TcdB in healthy blood donors (Viscidi et al.,
1983; Bacon and Fekety, 1994), and a low antitoxin serum level
in patients that are predisposed for recurrent, prolonged or
severe CDI (Salcedo et al., 1997; Kyne et al., 2000; Table 1).
After a successful study in children (Leung et al., 1991) IVIG
has been used in several small, mostly retrospective and non-
randomized studies with elderly patients suffering from recurrent
(Beales, 2002; Wilcox, 2004) or severe CDI (Salcedo et al., 1997;
McPherson et al., 2006; Juang et al., 2007; Shah et al., 2014;
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Shahani and Koirala, 2015; Table 2). So far, there is a lack of
robust evidence of a beneficial therapeutic effect of IVIG due to
the absence of a sufficiently powered randomized controlled trial
(Negm et al., 2017). In 2005, a randomized placebo- controlled
interventional study planned for 40 patients with severe relapsing
or refractory CDI (ClinicalTrials.gov NCT00177970) was started
and prematurely terminated. The sponsor states that they were
unable to receive IVIG free of cost from a pharmaceutical
company to continue.
In addition to the lack of consensus regarding optimal dose
and timing of IVIG administration and patient selection, the
quality of IVIG is a pivotal factor. Plasma or blood of 1,000–
100,000 healthy donors is used for IVIG manufacturing and
the compositions of plasma donor pools are not standardized.
Recently, three commercially available IVIG preparations were
screened for their reactivity to a panel of seven CD antigens.
They showed significant differences in antigen binding and
toxin neutralization, which are considered as the predominant
mode of action of IVIG against CDI (Negm et al., 2017).
Selected sourcing of donors with naturally occurring anti-toxin
antibodies for the manufacturing of IVIG with standardized
elevated specific antibody levels is feasible (Wasserman et al.,
2016). It is questionable if the market size of severe and rCDI
and predominance of low-cost medication can offer an incentive
to invest into a specialized IVIG.
As a blood-derived product, IgG pool carries a potential
(low) risk for blood-borne disease transmission (Chapel, 1999)
and contains batch-to-batch variability. Additionally, only a
small fraction of antibodies bind the target of interest. The
biodistribution of IVIG outside the bloodstream is poorly
understood (Brandtzaeg and Baklien, 1976; Wasserman et al.,
2012; Nikpoor et al., 2015), and it is unclear if the concentration
of antibody that reaches the site of infection could be sufficient to
exert the desired effect.
Furthermore, IVIG may not be cost-effective and would not
relieve the financial burden on health care. While each CDI
episode costs $3,500–5,042 (Dubberke et al., 2008), each IVIG
administration is calculated at $4551.25 (Blackhouse et al., 2010).
ANTIBODIES FOR ORAL APPLICATION
AGAINST CDI
Oral delivery of antibodies to target pathogens restricted to
the gastrointestinal tract provides a highly attractive treatment
strategy. A needle-free application directly on the affected site
may result in a higher efficacy with reduced side-effects at a lower
dose (Jones and Martino, 2016). Human and bovine antibodies
have been used in the past to treat CDI.
Human Antibodies
A human IgA and IgG pool (Tjellström et al., 1993; Saturno,
2006) derived from healthy blood donors was successfully used
to orally treat children with severe CDI resistant to standard
treatment (Table 2). Consistent with findings for infants orally
treated with human IgG (Blum et al., 1981), IgA remained
restricted to the gastrointestinal tract and did not enter the blood
stream (Casswall et al., 1996).
Bovine Antibodies
Hyperimmune bovine colostrum (HBC) or milk is an easily
scalable and cost-effective source (USD$1/gram antibody;
Hutton et al., 2017) for orally applicable antibodies with a strong
safety profile. It is produced by vaccination of cows during
gestation, and is rich in targeted IgG or secretory IgA (sIgA).
HBC derived from cows that were immunized with
recombinant mutants of TcdA and TcdB showed a therapeutic
efficacy in gnotobiotic piglets with diarrhea due to CDI
(Sponseller et al., 2015).
A single-site, open, crossover, clinical phase I study on six
healthy volunteers was performed to analyse the survival of
bovine IgG in the human gastrointestinal tract after application
of a single oral dose. Antibody-enriched colostral immune whey
protein concentrate (BIC) was derived from cows immunized
with either a toxoid derived from culture medium of toxigenic
CD containing both TcdA and B, or a toxoid of purified TcdA
(Kelly et al., 1997). Antibody within enteric coated capsules could
be recovered to about 30% of the initial dose in stool while
retaining its specific toxin-neutralizing activity. Based on in vitro
and preclinical findings, it was assumed that the bovine IgG could
neutralize CD toxins within the colonic lumen (Kelly et al., 1997).
This study also claimed bovine IgG concentrate against CD to be
safe for oral use in humans. The following single site, open, phase
I study was performed on six volunteers with an end ileostomy to
examine safety and bioavailability of a single oral dose. This study
showed the recovery of about 50% of the orally applied antibody
and a retained activity. It also revealed the difficulty of properly
formulating the oral antibody therapy for patients with abnormal
mouth to ileum transit times (Warny et al., 1999).
Immune whey protein concentrate derived from mature milk
of cows vaccinated with formaldehyde-inactivated whole CD
cells (VPI10463) and toxoid prepared from the CD culture
filtrate contained a high concentration of specific sIgA antibodies
(Schmautz et al., 2018; Table 1). This product, namedMucoMilk,
was intended to serve as “clinical nutrition” (not medication) for
patients with CDI and considered to be safe (Young et al., 2007).
The prevention of relapses of CDI was evaluated in a prospective
uncontrolled cohort study enrolling 16 patients with CDI. The
whey concentrate was applied subsequently to standard antibiotic
treatment. During a follow-up period of median 333 days, none
of the patients had experienced a relapse (van Dissel et al.,
2005). A following non-blinded, clinical cohort study applying
the same treatment scheme on 101 patients showed a reduction
of recurrence by about 50% (van Dissel et al., 2005; Numan et al.,
2007; Bauer et al., 2008; Bauer and van Dissel, 2009; Table 2).
Next, a controlled, double-blind, randomized, parallel-group,
multicenter trial with concentrated colostral immune whey from
cows vaccinated with formaldehyde-inactivated whole CD cells
(T-37067, T-36842), named Cediff, was performed (Table 1).
Cediff was comparedwithmetronidazole against rCDI in patients
that already encountered at least one episode. Although only a
small number of patients were included, the recurrence rate of
both treatment groups was similar (Mattila et al., 2008; Table 2).
Further development was stopped.
Recently, a phase 1/2, randomized, double blind, placebo-
controlled clinical study started enrolling patients with primary
and rCDI, to evaluate safety and tolerability of hyper-immune
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bovine colostrum powder (IMM-529) together with standard-
of-care (ClinicalTrials.gov NCT03065374). IMM-529 is derived
from cows vaccinated with TcdB, vegetative cells and endospores
of CD (Hutton et al., 2017; Table 1). In contrast to previous
approaches (Korhonen et al., 2000) the immune colostrum
powder is produced as pharmaceutical.
PERSPECTIVE
Further antibodies against CDI are in preclinical development,
such as avian antibodies against TcdA and B (Kink andWilliams,
1998) or spores (Pizarro-Guajardo et al., 2017) and fully human
polyclonal IgG obtained by immunization of transgenic cattle
with a trivalent and quadravalent toxin vaccine (Tian et al., 2017).
Smaller antibody formats such as a tetravalent bispecific
heavy-chain-only single domain (VHH) antibody against TcdA
and B features neutralization in a subnanomolar range and
efficacy in animal models of CDI and is deliverable by gene
therapy (Yang et al., 2014, 2016). Engineered lactobacilli that
produce variable domains of heavy chain only antibodies against
CD toxins show partial protection in a hamster model (Andersen
et al., 2016).
Fully functional antibodies that consist of heavy chains only
are named nanobodies. Nanobodies against binary toxin (Unger
et al., 2015) and surface proteins of CD (Kandalaft et al., 2015)
as well as variable domains derived from cartilaginous shark
IgNAR (Krah et al., 2016) have shown effects in vitro. A camelid
single domain antibody against TcdA could be easily optimized
by an affinity maturation platform and could serve as an
alternative therapeutic modality in the future (Sulea et al., 2018).
A novel humanized monoclonal antibody recognizes a single,
highly conserved epitope on the TcdB glucosyltransferase
domain and neutralizes TcdB from various CD strains
(Kroh et al., 2018).
CONCLUSION
Taken together, antibodies such as bezlotoxumab have proven to
be capable of protecting from rCDI, while mostly being directed
against toxins. A better understanding of virulence factors of
CD could help to broaden the repertoire of therapeutic targets
and may result in antibodies also applicable for severe and
refractory CDI or CDI caused by “hypervirulent” strains. Due to
their property of maintaining the integrity of the gut microflora
and providing no selective pressure for escape mutants (Steele
et al., 2013), polyclonal antibodies could act synergistically with
antibiotics and FMT and could easily be integrated in treatment
regimens, provided that their costs are competitive with current
therapies. Oral antibodies have the clear advantage that they
could be applied not only at the clinic but also at the patient’s
home.
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